文献速递新生儿儿童呼吸

肺超声评分预测极早产儿表面活性物质需求

Lung Ultrasound Score Predicts Surfactant Need in Extremely Preterm Neonates.
PubMed 文献 · Pediatrics · 2018-08-14

该前瞻性队列诊断准确性研究纳入133例胎龄≤30周、接受持续气道正压通气治疗的呼吸窘迫综合征(RDS)早产儿,评估肺超声评分(LUS)预测表面活性物质治疗及再治疗需求的准确性。LUS与氧合指数显著相关(ρ=0.6,P<.0001),预测首次表面活性物质需求的AUC为0.94(95%CI:0.90-0.98,P<.0001),预测再治疗的AUC为0.803(95%CI:0.72-0.89,P<.0001),总体准确率分别为89%和72%。

要点

  • LUS与氧合指数显著相关(ρ=0.6),校正胎龄后仍显著(P<.0001)。
  • LUS预测首次表面活性物质需求的AUC为0.94(95%CI:0.90-0.98)。
  • LUS预测表面活性物质再治疗的AUC为0.803(95%CI:0.72-0.89)。

核心结论

  • LUS可能用于预测极早产儿RDS的表面活性物质替代治疗需求。

研究设计与样本

  • 2015至2016年在三级学术中心开展的前瞻性队列诊断准确性研究,纳入133例胎龄≤30周、接受持续气道正压通气治疗的RDS早产儿。

主要发现

  • 133例中68例(51%)接受1剂表面活性物质,19例(14%)接受2剂。
  • LUS与氧合指数显著相关(ρ=0.6;P<.0001),校正胎龄后仍显著(P<.0001)。
  • LUS预测首次表面活性物质需求的AUC为0.94(95%CI:0.90-0.98;P<.0001)。
  • LUS预测表面活性物质再治疗的AUC为0.803(95%CI:0.72-0.89;P<.0001)。
  • 预测表面活性物质治疗和再治疗的总体准确率分别为89%和72%。

关键数值与推荐

  • 表面活性物质依据欧洲指南推导的氧需求阈值给予,LUS未用于指导治疗。

临床怎么用

  • 在极早产儿RDS接受持续气道正压通气时,可考虑用LUS辅助预测是否需要表面活性物质及再治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There are several lung ultrasound scores (LUS) for evaluating lung aeration in critically ill adults with restrictive lung disorders. A modified LUS adapted for neonates correlates well with oxygenation and is able to be used to predict the need for surfactant in preterm neonates with respiratory distress syndrome (RDS). However, no data are available for extremely preterm neonates for whom timely surfactant administration is especially important. We hypothesized that LUS might be reliable in extremely preterm neonates with RDS who are treated with continuous positive airway pressure. We aimed to determine the diagnostic accuracy of LUS in predicting the need for surfactant treatment and re-treatment in this population. METHODS: We performed a prospective cohort diagnostic accuracy study between 2015 and 2016 in a tertiary-care academic center. Inborn neonates at ≤30 weeks' gestation with RDS treated with continuous positive airway pressure were eligible. Surfactant was given on the basis of oxygen requirement thresholds derived from European guidelines, and a LUS was not used to guide surfactant treatment. We calculated the LUS after admission and analyzed its diagnostic accuracy to predict surfactant treatment and re-treatment. RESULTS: We enrolled 133 infants; 68 (51%) received 1 dose of surfactant and 19 (14%) received 2 surfactant doses. A LUS is significantly correlated with oxygenation index (ρ = 0.6; P < .0001) even after adjustment for gestational age (P < .0001). A LUS can be used to accurately predict the need for the first surfactant dose (area under the curve = 0.94; 95% confidence interval: 0.90-0.98; P < .0001) and also the need for surfactant redosing (area under the curve = 0.803; 95% confidence interval: 0.72-0.89; P < .0001). The global accuracy for the prediction of surfactant treatment and re-treatment is 89% and 72%, respectively. CONCLUSIONS: LUS may be used to predict the need for surfactant replacement in extremely preterm neonates with RDS.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. De Martino L, Yousef N, Ben-Ammar R, et al. Lung Ultrasound Score Predicts Surfactant Need in Extremely Preterm Neonates. Pediatrics. 2018. PMID: 30108142. doi:10.1542/peds.2018-0463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。